Literature DB >> 27107696

miR-542-3p suppresses invasion and metastasis by targeting the proto-oncogene serine/threonine protein kinase, PIM1, in melanoma.

Zhen Rang1, Ge Yang1, You-Wei Wang1, Fan Cui2.   

Abstract

Aberrant microRNAs (miRNAs) contribute to metastasis of various cancer types, including melanoma. miR-542-3p has been characterized as a tumor suppressor in several cancers. However, the exact expression patterns of miR-542-3p and the precise molecular mechanisms underlying its role in melanoma require further exploration. In the current study, we demonstrated that miR-542-3p is significantly downregulated in melanoma cell lines and clinical specimens. Exogenous expression of miR-542-3p resulted in marked inhibition of melanoma cell migration, invasion and epithelial-mesenchymal transition (EMT) in vitro and lung metastasis in vivo. The proto-oncogene serine/threonine protein kinase, PIM1, was identified as a direct target of miR-542-3p using luciferase reporter assay, qRT-PCR and western blot analyses. Overexpression of PIM1 partially rescued miR-542-3p-mediated suppression of cell migration, invasion and EMT. Our results collectively indicate that miR-542-3p serves as a metastasis suppressor in melanoma, supporting its utility as a promising therapeutic candidate.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Invasion; Melanoma; Migration; PIM1; miR-542-3p

Mesh:

Substances:

Year:  2016        PMID: 27107696     DOI: 10.1016/j.bbrc.2016.04.093

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  27 in total

1.  Alpinumisoflavone induces apoptosis in esophageal squamous cell carcinoma by modulating miR-370/PIM1 signaling.

Authors:  Yantao Han; Xiuwei Yang; Ning Zhao; Jianjun Peng; Hui Gao; Xia Qiu
Journal:  Am J Cancer Res       Date:  2016-12-01       Impact factor: 6.166

2.  miR-542-3p inhibits colorectal cancer cell proliferation, migration and invasion by targeting OTUB1.

Authors:  Long Yuan; Peng Yuan; Huijuan Yuan; Zhenlei Wang; Zengci Run; Guanglong Chen; Peng Zhao; Benling Xu
Journal:  Am J Cancer Res       Date:  2017-01-01       Impact factor: 6.166

Review 3.  Micro RNAs Promoting Growth and Metastasis in Preclinical In Vivo Models of Subcutaneous Melanoma.

Authors:  Ulrich H Weidle; Simon AuslÄnder; Ulrich Brinkmann
Journal:  Cancer Genomics Proteomics       Date:  2020 Nov-Dec       Impact factor: 4.069

4.  MiR-542-3p Suppresses Neuroblastoma Cell Proliferation and Invasion by Downregulation of KDM1A and ZNF346.

Authors:  Qiang Wei; Zhao Guo; Dong Chen; Xinjian Jia
Journal:  Open Life Sci       Date:  2020-04-10       Impact factor: 0.938

Review 5.  MicroRNA Signature in Melanoma: Biomarkers and Therapeutic Targets.

Authors:  Soudeh Ghafouri-Fard; Mahdi Gholipour; Mohammad Taheri
Journal:  Front Oncol       Date:  2021-04-22       Impact factor: 6.244

6.  Piceatannol induced apoptosis through up-regulation of microRNA-181a in melanoma cells.

Authors:  Maotao Du; Zhong Zhang; Tao Gao
Journal:  Biol Res       Date:  2017-10-17       Impact factor: 5.612

7.  miR-33a is a tumor suppressor microRNA that is decreased in prostate cancer.

Authors:  Omer Faruk Karatas; Jianghua Wang; Longjiang Shao; Mustafa Ozen; Yiqun Zhang; Chad J Creighton; Michael Ittmann
Journal:  Oncotarget       Date:  2017-07-24

Review 8.  Xmrks the Spot: Fish Models for Investigating Epidermal Growth Factor Receptor Signaling in Cancer Research.

Authors:  Jerry D Monroe; Faiza Basheer; Yann Gibert
Journal:  Cells       Date:  2021-05-07       Impact factor: 6.600

9.  MicroRNA-542-3p inhibits oral squamous cell carcinoma progression by inhibiting ILK/TGF-β1/Smad2/3 signaling.

Authors:  Bin Qiao; Jing-Hua Cai; Alfred King-Yin Lam; Bao-Xia He
Journal:  Oncotarget       Date:  2017-08-07

Review 10.  miRNAs, Melanoma and Microenvironment: An Intricate Network.

Authors:  Gabriele Romano; Lawrence N Kwong
Journal:  Int J Mol Sci       Date:  2017-11-07       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.